Skip to main content

Table 1 Baseline characteristics and CMR parameters for patients with and without the primary outcome

From: Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction

Parameters All patients (n = 172) Patients without the primary outcome (n = 129) Patients with the primary outcome (n = 43) P value
Age (years) 56.4 ± 14.3 57.0 ± 14.6 54.8 ± 13.5 0.398
Male gender, n (%) 116 (67.4) 85 (65.9) 31 (72.1) 0.452
Mean arterial pressure (mmHg) 84 ± 13 86 ± 13 80 ± 12 0.015
Hypertension, n (%) 58 (33.7) 44 (34.1) 14 (32.6) 0.852
Diabetes mellitus, n (%) 36 (20.9) 25 (19.4) 11 (25.6) 0.387
Dyslipidemia, n (%) 11 (6.4) 8 (6.2) 3 (7.0) 0.857
Current smoker, n (%) 49 (28.5) 37 (28.7) 12 (27.9) 0.734
Chronic kidney diseasea, n (%) 31 (18.0) 21 (16.3) 10 (23.3) 0.303
Previous CVA, n (%) 4 (2.3) 1 (0.8) 3 (7.0) 0.049
Body mass index (kg/m2) 24.0 ± 4.5 24.2 ± 4.5 23.5 ± 4.4 0.347
ECG at baseline     
 Heart rate (bpm) 83 ± 20 84 ± 19 83 ± 22 0.883
 Left bundle-branch block, n (%) 31 (18.0) 23 (17.8) 8 (19.0) 0.859
 QRS duration (ms) 113 ± 29 112 ± 30 117 ± 29 0.305
Laboratory data     
 Serum creatinine (mg/dl) 0.97 ± 0.27 0.96 ± 0.25 1.01 ± 0.31 0.247
 Na (mmol/l) 139.6 ± 3.3 140.2 ± 2.8 137.6 ± 3.8 < 0.001
 ln(NT-proBNP) (pg/ml) 7.22 ± 1.27 7.08 ± 1.29 7.60 ± 1.16 0.022
Cardiac medications     
 Beta-blockers, n (%) 120 (69.8) 87 (67.4) 33 (76.7) 0.250
 ACE-inhibitors/ARB, n(%) 134 (77.9) 104 (80.6) 39 (90.7) 0.126
 Spironolactone, n (%) 101 (58.7) 74 (57.4) 27 (62.8) 0.531
 Diuretics, n (%) 125 (72.7) 93 (72.1) 32 (74.4) 0.767
 Digoxin, n (%) 33 (19.2) 21 (16.3) 12 (27.9) 0.094
  1. Primary outcome: all-cause death, heart transplantation during follow-up. Values are mean ± SD, n(%)
  2. aChronic kidney disease was defined as eGFR < 60 ml/min/1.73m2, calculated using the 4-component MDRD study equation
  3. Abbreviations: ACE angiotensin-converting-enzyme, ARB angiotensin II receptor blockers, BNP B-type natriuretic peptide, CVA cerebrovascular accident ECG electrocardiography